MktsMarkets

Inhibikase Therapeutics, Inc.
NASDAQ: IKTKey statistics
IKT News
Stories mentioning IKT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 10,839 | 6,358 | 7,650 | 5,271 | 10,514 | 7,194 | 4,190 | 3,076 |
| Sales General & Admin | 7,376 | 6,774 | 5,612 | 5,920 | 5,249 | 5,735 | 1,638 | 1,975 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (17,842) | (13,776) | (12,768) | (10,832) | (14,598) | (12,929) | (5,827) | (5,051) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income (Loss) | (16,381) | (12,734) | (11,930) | (9,916) | (13,679) | (12,132) | (5,778) | (4,960) |
| Earnings Per Share (Basic) | (0.10) | (0.13) | (0.13) | (0.11) | (0.15) | (0.51) | (0.65) | (0.66) |
| Earnings Per Share (Diluted) | (0.10) | (0.13) | (0.13) | (0.11) | (0.15) | (0.51) | (0.65) | (0.66) |
| Weighted Average Shares Outstanding (Basic) | 172,307 | 98,310 | 90,051 | 90,010 | 89,537 | 23,712 | 8,883 | 7,536 |
| Weighted Average Shares Outstanding (Diluted) | 172,307 | 98,310 | 90,051 | 90,010 | 89,537 | 23,712 | 8,883 | 7,536 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About IKT
Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a stock listed on the Nasdaq Stock Market under the ticker symbol IKT. It last traded at $1.55 (Oct 30, 2026, 4:00 PM ET), down 7.2% on the day. That gives Inhibikase Therapeutics a market capitalisation of $216.3M.
Over the past 52 weeks IKT has traded between $1.33 and $2.61.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $16.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$16.4M |
| Dec 31, 2025 | $0 | -$12.7M |
| Sep 30, 2025 | $0 | -$11.9M |
| Jun 30, 2025 | $0 | -$9.9M |
From Inhibikase Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…